Bausch + Lomb presents Phase 4 MIEBO contact lens wear study at Academy 2026 Anaheim

By Public Technologies
  • Bausch + Lomb set 28 scientific posters for Academy 2026 Anaheim, Sept. 30 to Oct. 3, 2026.
  • New Phase 4 research on MIEBO assessed use around contact lens wear, focusing on tolerability and patient experience.
  • Real-world analyses of concomitant XIIDRA and MIEBO in dry eye disease reported improvements in signs and symptoms.
  • Additional studies on a hyaluronic acid formulation of LUMIFY highlighted rapid redness relief that held up over time.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.